Apr 17, 2025
When people caught Covid in the early months of 2020, they normally reached for symptomatic control using NSAIDs and Paracetamol. They are affordable, widely available over the counter, have a well-established benefit-risk profile and are good at managing fever, body...
Mar 13, 2025
Charles Joynson, WaveData MD, analyses Naproxen E/C Tabs long-term pricing. This consequently triggered pricing and portfolio managers to re-evaluate these products in the light of continuing unprofitability. That then shook some manufacturers out of the market...
Feb 6, 2025
Tadalafil Tabs were launched in November 2017 in competition with Eli Lilly’s Cialis Tabs. Generic prices post launch were around the £10.00 mark, significantly lower than the Cialis reimbursement price at the time which was £54.99. However, eight months after launch...
Feb 6, 2025
Over the last ten years Quetiapine Tabs 100mg 60 has had 4 sets of concessions, making it a risky product to make and distribute. WaveData wanted to find the ‘trigger’ prices which forced manufacturers out of the market due to unprofitability. The first of...
Feb 6, 2025
This suspension is one that has been hovering on the edge of unprofitability for a long time and has seen more concessions granted (32) in 2023 – 2024 that any other generic. Between Nov 2017 and Dec 2019 market prices averaged close to or below £4.00. This...
Jan 6, 2025
This product has seen its market price decay from around £13.00 in 2017 – 2020 to a low of £4.29 in September 2024. This may have pushed this combined product, complicated to make due to its combined and device characteristics, into unprofitability as it has...
